What is the appropriate management for an actively bleeding patient who presents with an ST-elevation myocardial infarction (STEMI)?

Management of Actively Bleeding STEMI Patients

Active bleeding is an absolute contraindication to fibrinolytic therapy in STEMI patients, and primary percutaneous coronary intervention (PCI) becomes the mandatory reperfusion strategy 1.

Immediate Reperfusion Strategy

When a STEMI patient presents with active bleeding, you must proceed directly to primary PCI and completely avoid fibrinolytic therapy. The 2013 ACC/AHA guidelines explicitly list "active bleeding or bleeding diathesis (excluding menses)" as an absolute contraindication to fibrinolytics 1. This is non-negotiable—the bleeding risk from thrombolytics in an already bleeding patient far outweighs any potential benefit.

Primary PCI Approach

• Vascular access: Use radial artery access rather than femoral to minimize bleeding complications at the access site 2
• Stenting considerations: In extreme bleeding scenarios, consider plain old balloon angioplasty (POBA) without stent deployment to avoid the mandatory dual antiplatelet therapy (DAPT) that stents require 3, 4
• Rationale: If you cannot safely administer DAPT due to active bleeding, deploying a stent creates immediate risk of stent thrombosis

Antithrombotic Management During Active Bleeding

This requires walking a tightrope between preventing stent thrombosis and exacerbating hemorrhage:

Anticoagulation During PCI

• Bivalirudin is preferred over unfractionated heparin in high bleeding risk patients 5, 6
• Bivalirudin has a shorter half-life and more predictable pharmacokinetics, allowing better control in bleeding situations
• Avoid glycoprotein IIb/IIIa inhibitors unless absolutely necessary for high thrombus burden—they significantly increase bleeding risk 7

Antiplatelet Therapy Strategy

For patients who can tolerate some antiplatelet therapy:

• Aspirin 162-325 mg loading dose remains essential 1
• Consider intravenous cangrelor as the P2Y12 inhibitor rather than oral agents 3
  • Cangrelor is the only IV P2Y12 inhibitor available
  • It has a 3-5 minute half-life, allowing rapid on/off control
  • Can be discontinued immediately if bleeding worsens, then restarted when bleeding is controlled
  • This provides critical flexibility that oral agents (clopidogrel, prasugrel, ticagrelor) cannot offer

For patients with severe, life-threatening bleeding:

• Aspirin alone may be necessary initially
• Delay P2Y12 inhibitor until bleeding source is controlled
• Accept the increased thrombotic risk as the lesser of two evils

Critical Decision Points

Source Control First

Before or concurrent with PCI, identify and control the bleeding source when possible. A patient bleeding from a peptic ulcer needs endoscopy; a patient with intracranial hemorrhage needs neurosurgical evaluation. The cardiac intervention and bleeding management must proceed in parallel.

Stent vs. No Stent Decision

• If DAPT is absolutely contraindicated: Perform POBA only 3, 4
• If short-term DAPT is feasible: Deploy drug-eluting stent with plan for abbreviated DAPT duration once bleeding controlled
• If uncertain: POBA is safer—you can always return for staged stenting after bleeding resolves

Post-PCI Management

Once the acute intervention is complete:

• Continuous reassessment of bleeding vs. thrombotic risk is essential 2
• Monitor hemoglobin, platelet count, and bleeding sites closely
• If cangrelor was used, transition to oral P2Y12 inhibitor only when bleeding is definitively controlled
• Consider shorter DAPT duration (1-3 months) in high bleeding risk patients with newer-generation drug-eluting stents

Common Pitfalls to Avoid

1. Never give fibrinolytics to an actively bleeding patient—this seems obvious but bears repeating given the time-sensitive nature of STEMI
2. Don't reflexively use femoral access—radial access reduces bleeding complications significantly
3. Don't deploy a stent if you cannot commit to DAPT—bare metal or drug-eluting, all stents require antiplatelet therapy
4. Don't forget that bleeding risk is dynamic—what's contraindicated today may be safe tomorrow once bleeding is controlled

The evidence consistently shows that while these patients require individualized approaches beyond standard guidelines 3, 4, the fundamental principle remains: primary PCI with bleeding-conscious antithrombotic strategies is the only acceptable reperfusion approach for actively bleeding STEMI patients.